Stock Track | Humacyte Soars Over 50% as FDA Approves SYMVESS for Vascular Trauma Treatment

Stock Track12-20 23:02

Shares of biotechnology firm Humacyte, Inc. (HUMA) skyrocketed by a staggering 52.87% in Friday's pre-market trading session. This massive surge came after the company announced late on Thursday that the U.S. Food and Drug Administration (FDA) has granted full approval for its bioengineered human tissue product SYMVESS (acellular tissue engineered vessel-tyod).

The FDA approval allows SYMVESS to be used in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when an autologous vein graft is not feasible. This marks a significant milestone for Humacyte and the field of regenerative medicine.

SYMVESS is a first-of-its-kind, off-the-shelf implantable bioengineered human tissue that can serve as a vascular conduit for arterial replacement and repair. In clinical testing, SYMVESS demonstrated high rates of blood flow patency and low rates of complications such as amputation and infection when used for treating various traumatic arterial injuries like gunshot wounds, car accidents, and blast injuries.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163400241?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163400241","market":"us","top_or_hot":-1,"title":"Stock Track | Humacyte Soars Over 50% as FDA Approves SYMVESS for Vascular Trauma Treatment","media":"Stock Track","content":"<p>Shares of biotechnology firm Humacyte, Inc. (HUMA) skyrocketed by a staggering 52.87% in Friday's pre-market trading session. This massive surge came after the company announced late on Thursday that the U.S. Food and Drug Administration (FDA) has granted full approval for its bioengineered human tissue product SYMVESS (acellular tissue engineered vessel-tyod).</p>\n\n<p>The FDA approval allows SYMVESS to be used in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when an autologous vein graft is not feasible. This marks a significant milestone for Humacyte and the field of regenerative medicine.</p>\n\n<p>SYMVESS is a first-of-its-kind, off-the-shelf implantable bioengineered human tissue that can serve as a vascular conduit for arterial replacement and repair. In clinical testing, SYMVESS demonstrated high rates of blood flow patency and low rates of complications such as amputation and infection when used for treating various traumatic arterial injuries like gunshot wounds, car accidents, and blast injuries.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Humacyte Soars Over 50% as FDA Approves SYMVESS for Vascular Trauma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Humacyte Soars Over 50% as FDA Approves SYMVESS for Vascular Trauma Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n2024-12-20 23:02 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of biotechnology firm Humacyte, Inc. (HUMA) skyrocketed by a staggering 52.87% in Friday's pre-market trading session. This massive surge came after the company announced late on Thursday that ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HUMA","symbol_name":"Humacyte, Inc.","start_time":0,"source_url":"","article_id":"1163400241","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163400241","pubTimestamp":1734706950,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of biotechnology firm Humacyte, Inc.  skyrocketed by a staggering 52.87% in Friday's pre-market trading session. This massive surge came after the company announced late on Thursday that the U.S. Food and Drug Administration  has granted full approval for its bioengineered human tissue product SYMVESS .The FDA approval allows SYMVESS to be used in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when an aut","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HUMA":"Humacyte, Inc."},"translate_title":"FDA批准SYMVESS用于血管创伤治疗，Humacyte股价飙升逾50%","themeId":"2fa1cf6b255f3c244a082df08bbda9a2","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HUMA":1},"content_text":"Shares of biotechnology firm Humacyte, Inc. (HUMA) skyrocketed by a staggering 52.87% in Friday's pre-market trading session. This massive surge came after the company announced late on Thursday that the U.S. Food and Drug Administration (FDA) has granted full approval for its bioengineered human tissue product SYMVESS (acellular tissue engineered vessel-tyod).\nThe FDA approval allows SYMVESS to be used in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when an autologous vein graft is not feasible. This marks a significant milestone for Humacyte and the field of regenerative medicine.\nSYMVESS is a first-of-its-kind, off-the-shelf implantable bioengineered human tissue that can serve as a vascular conduit for arterial replacement and repair. In clinical testing, SYMVESS demonstrated high rates of blood flow patency and low rates of complications such as amputation and infection when used for treating various traumatic arterial injuries like gunshot wounds, car accidents, and blast injuries.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163400241"}